BPC-157 for Tendon and Ligament Research

For laboratory research use only. This page summarises published scientific literature on BPC-157 for Tendon in plain English, in a neutral research style. It is not medical advice and contains no guidance on doses, administration or human use.

Last updated: April 2026 · UK research-grade reference · For laboratory research use only — not for human consumption

Table of Contents

• 1. What BPC-157 is and why tendon research matters
• 2. Achilles tendon — the foundational rodent evidence
• 3. Medial collateral ligament — the ligament repair model
• 4. Quadriceps and gastrocnemius muscle injury
• 5. Mechanism — VEGFR2, FAK-paxillin, nitric oxide
• 6. Angiogenesis and the early-healing phase
• 7. Collagen remodelling and biomechanical strength research applications
• 11. Cross-reference to TB-500 research
• 15. References

1. What BPC-157 is and why tendon research matters

BPC-157 is a synthetic 15-amino-acid pentadecapeptide (sequence: GEPPPGKPADDAGLV) derived from a region of the human gastric juice protein Body Protection Compound. It was identified and characterised primarily by the research group of Predrag Sikirić at the University of Zagreb, beginning in the 1990s and continuing through the 2020s, with additional contributions from independent research groups primarily in East Asia and Europe.

The tendon and ligament research programme has particular depth because tendon injury is a high-prevalence, poorly served indication in sports medicine and orthopaedic surgery. Tendons heal slowly — the hypovascular environment and sparse fibroblast population limit early repair — and existing pharmacological options are limited. A peptide shown to accelerate tendon repair in controlled rodent models is a candidate for translational investigation, though human trial evidence remains limited.

2. Achilles tendon — the foundational rodent evidence

• Macroscopic healing assessment: BPC-157 groups showed faster gap closure and tendon reconstitution.
• Histological scoring: greater fibroblast density, earlier collagen fibre alignment, and greater neovascularisation.
• Biomechanical testing: higher load-to-failure tensile strength at day 14 in BPC-157 groups compared to saline.
• Functional assessment: earlier restoration of weight-bearing and locomotor performance.

Subsequent studies have broadly replicated this pattern in related models. The effect sizes across studies vary — as is normal in animal injury models — but the direction is consistent.

3. Medial collateral ligament — the ligament repair model

• Histological healing scores at 30 and 60 days
• Biomechanical tensile strength of the healed ligament
• Reduction in scar tissue disorganisation

This suggested BPC-157’s effects are not specific to tendon — the mechanism engages generalised fibroblast-migration and angiogenesis pathways relevant to connective tissue repair broadly.

4. Quadriceps and gastrocnemius muscle injury

Skeletal muscle injury models include: crush injury of gastrocnemius, transection of quadriceps, and denervation studies. Across these, BPC-157 has been reported to accelerate:

• Recovery of muscle fibre architecture
• Reduction in inflammation markers in the injury zone
• Restoration of functional muscle contraction

For research design, this suggests BPC-157’s repair effects are shared across several connective and skeletal tissue injury paradigms, providing a coherent set of candidate preclinical models.

5. Mechanism — VEGFR2, FAK-paxillin, nitric oxide

Three principal mechanistic axes have emerged from the literature:

1. VEGFR2 activation: Hsieh et al. (2017) and subsequent work demonstrated BPC-157 engages vascular endothelial growth factor receptor 2 signalling in a VEGF-independent manner, driving downstream endothelial cell proliferation and tube formation — the angiogenic process essential for early-phase tissue repair.
2. FAK-paxillin pathway: Chang et al. (2011) showed BPC-157 activates focal adhesion kinase and paxillin in tendon fibroblasts, promoting fibroblast migration to injury sites — a rate-limiting step in tendon repair.
3. Nitric oxide system modulation: Multiple studies document BPC-157 interactions with the NO pathway — both enhancement of NO production in injury contexts and protection against NO-related cytotoxicity in oxidative-stress models. The NO system is deeply involved in vascular tone and tissue perfusion during repair.

Additional signalling pathways implicated in various studies include EGR1 (early growth response 1), matrix metalloproteinase modulation, and the dopaminergic system. The mechanism is pleiotropic — which is both a feature (broad applicability) and a challenge (no single “clean” pharmacological target for drug-development purposes).

6. Angiogenesis and the early-healing phase

The earliest phase of tendon or ligament healing is dominated by inflammation and early angiogenesis — blood vessels must grow into the injury zone to deliver oxygen, nutrients and immune cells. BPC-157’s VEGFR2-mediated angiogenic effect appears to accelerate this phase, measurable in rodent studies as earlier appearance of neovascularisation in histological sections at days 3-7 post-injury.

Beyond the injury zone itself, BPC-157 has been shown to protect and restore vascular perfusion in ischaemic and hypoperfusion models (stroke, myocardial infarction models, vascular occlusion) — further supporting the central role of angiogenesis in its mechanism.

7. Collagen remodelling and biomechanical strength research applications

Tendon repair is a three-phase process: inflammation (days 0-7), proliferation / matrix deposition (days 7-21), and remodelling (weeks 3 through several months). BPC-157’s effects span all three phases in the rodent data:

• Inflammatory phase: modulation of inflammation markers and earlier transition to proliferation
• Proliferation phase: increased fibroblast density and collagen synthesis
• Remodelling phase: better-aligned collagen fibre architecture and higher load-to-failure biomechanical strength

The biomechanical strength research applications signal is the most clinically translatable endpoint — it represents actual functional tendon performance, not just histology.

11. Cross-reference to TB-500 research

See our TB-500 UK Research Guide for the parallel TB-500 literature review.

Limits of the evidence

Published findings come from specific study designs, often in cell systems or animals, and do not transfer automatically to other settings. A paper about a molecule is not proof that any particular batch has a given biological effect. Purity data show what is in a vial; they do not show sterility, safety or suitability for any use outside the laboratory.

Laboratory handling

• Store lyophilised powder sealed, cold (−20 °C for long-term storage), dry and protected from light.
• Let vials reach room temperature before opening to limit condensation.
• Prepare solutions with suitable laboratory solvents and calibrated equipment, and label each with lot number, concentration and date.
• Split solutions into single-use aliquots and avoid repeated freeze–thaw cycles.
• Use the peptide calculator for concentration arithmetic (mg/mL).

15. References

1. Staresinic M, Sebecic B, Patrlj L, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res 2003;21(6):976-983.
2. Krivic A, Anic T, Seiwerth S, et al. Achilles detachment in rat and stable gastric pentadecapeptide BPC 157: promoted tendon-to-bone healing and opposed corticosteroid aggravation. J Orthop Res 2006;24(5):982-989.
3. Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res 2010;28(9):1155-1161.
4. Chang CH, Tsai WC, Lin MS, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol 2011;110(3):774-780.
5. Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med 2017;95(3):323-333.
6. Sikirić P, Seiwerth S, Rucman R, et al. Stable Gastric Pentadecapeptide BPC 157 — Current Status in Wound Healing. Current Pharmaceutical Design 2018;24(18):1972-1989.
7. Sikirić P, Seiwerth S, Rucman R, et al. Brain-gut Axis and Pentadecapeptide BPC 157. Current Neuropharmacology 2016;14(8):857-865.
8. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res 2019;377(2):153-159.
9. Huang T, Zhang K, Sun L, et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther 2015;9:2485-2499.
10. Chang CH, Tsai WC, Hsu YH, et al. Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules 2014;19(12):19066-19077.

UK Research Cluster Hubs

• BPC-157 UK Research Guide
• TB-500 UK Research Guide
• GLP-1 Peptides Complete Research Reference
• Retatrutide UK Research Guide
• Tirzepatide UK Research Guide
• Research-Grade Peptides Standards Guide
• UK Research Peptide Buying Guide

Related research: BPC-157 research hub. For laboratory research use only.

For laboratory research use only. BPC-157 for Tendon sold by Peptides Lab UK is supplied strictly for in vitro laboratory research. It is not for human or veterinary use, and nothing on this page is medical advice or guidance on administration. UK purchasers are responsible for complying with all applicable legislation.